Disc Medicine (IRON) Competitors $47.13 +2.31 (+5.15%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IRON vs. ARDX, LSEA, PBYI, DBTX, QSI, RARE, BBIO, OGN, IMVT, and CYBNShould you be buying Disc Medicine stock or one of its competitors? The main competitors of Disc Medicine include Ardelyx (ARDX), Landsea Homes (LSEA), Puma Biotechnology (PBYI), Decibel Therapeutics (DBTX), Quantum-Si (QSI), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Organon & Co. (OGN), Immunovant (IMVT), and Cybin (CYBN). Disc Medicine vs. Ardelyx Landsea Homes Puma Biotechnology Decibel Therapeutics Quantum-Si Ultragenyx Pharmaceutical BridgeBio Pharma Organon & Co. Immunovant Cybin Disc Medicine (NASDAQ:IRON) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, community ranking, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings. Is IRON or ARDX more profitable? Disc Medicine has a net margin of 0.00% compared to Ardelyx's net margin of -31.02%. Disc Medicine's return on equity of -23.78% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -23.78% -22.62% Ardelyx -31.02%-39.73%-20.47% Which has preferable earnings and valuation, IRON or ARDX? Ardelyx has higher revenue and earnings than Disc Medicine. Ardelyx is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$76.43M-$3.67-12.84Ardelyx$124.46M11.52-$66.07M-$0.27-22.55 Do institutionals & insiders believe in IRON or ARDX? 83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 4.2% of Disc Medicine shares are owned by insiders. Comparatively, 5.9% of Ardelyx shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, IRON or ARDX? Disc Medicine has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Does the media refer more to IRON or ARDX? In the previous week, Ardelyx had 9 more articles in the media than Disc Medicine. MarketBeat recorded 22 mentions for Ardelyx and 13 mentions for Disc Medicine. Disc Medicine's average media sentiment score of 0.70 beat Ardelyx's score of 0.36 indicating that Disc Medicine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 3 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 4 Very Positive mention(s) 4 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend IRON or ARDX? Disc Medicine currently has a consensus price target of $66.40, indicating a potential upside of 40.89%. Ardelyx has a consensus price target of $11.67, indicating a potential upside of 91.57%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Ardelyx 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer IRON or ARDX? Ardelyx received 490 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 81.25% of users gave Disc Medicine an outperform vote while only 67.56% of users gave Ardelyx an outperform vote. CompanyUnderperformOutperformDisc MedicineOutperform Votes3981.25% Underperform Votes918.75%ArdelyxOutperform Votes52967.56% Underperform Votes25432.44% SummaryArdelyx beats Disc Medicine on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Disc Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for IRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRON vs. The Competition Export to ExcelMetricDisc MedicinePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.40B$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-12.849.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book3.335.324.665.02Net Income-$76.43M$153.56M$119.06M$225.46M7 Day Performance2.43%0.11%0.80%0.37%1 Month Performance-7.95%15.22%5.65%3.57%1 Year Performance2.68%41.14%36.76%29.44% Disc Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRONDisc Medicine3.7598 of 5 stars$47.13+5.2%$66.40+40.9%+2.5%$1.40BN/A-12.8478Short Interest ↓ARDXArdelyx4.1613 of 5 stars$5.88+1.9%$11.67+98.4%+54.6%$1.37B$210.00M-21.78267Analyst ForecastInsider SellingOptions VolumeAnalyst RevisionGap UpLSEALandsea Homes4.4536 of 5 stars$11.25+1.7%$14.67+30.4%+32.7%$407.01M$1.40B17.58380Upcoming EarningsPBYIPuma Biotechnology2.4928 of 5 stars$3.01+2.0%$7.00+132.6%+11.3%$145.20M$219.14M15.84185Upcoming EarningsAnalyst UpgradeNews CoverageDBTXDecibel TherapeuticsN/A$4.91-0.8%N/A+0.0%$123.39MN/A-1.9468High Trading VolumeQSIQuantum-Si2.8766 of 5 stars$0.75+0.7%$4.00+433.0%-35.4%$106.42M$1.70M-1.19150News CoverageRAREUltragenyx Pharmaceutical4.1907 of 5 stars$54.48+1.2%$85.08+56.2%+41.5%$4.53B$481.30M-7.461,276Upcoming EarningsBBIOBridgeBio Pharma4.5444 of 5 stars$24.16+1.3%$47.50+96.6%-4.4%$4.52B$219.12M-9.19400Upcoming EarningsOGNOrganon & Co.4.7 of 5 stars$17.40+1.4%$21.33+22.6%+23.2%$4.47B$6.35B4.4710,000Dividend AnnouncementNews CoverageIMVTImmunovant2.898 of 5 stars$30.22-0.9%$48.10+59.2%-12.2%$4.42BN/A-15.66120CYBNCybin1.8174 of 5 stars$10.28-1.2%$50.50+391.2%N/A$4.22BN/A-1.6950 Related Companies and Tools Related Companies Ardelyx Alternatives Landsea Homes Alternatives Puma Biotechnology Alternatives Decibel Therapeutics Alternatives Quantum-Si Alternatives Ultragenyx Pharmaceutical Alternatives BridgeBio Pharma Alternatives Organon & Co. Alternatives Immunovant Alternatives Cybin Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IRON) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
